Ukko Secures $40 Million in Series B Funding Led by Leaps by Bayer to Overcome Food Allergies and Sensitivities
Ukko Secures $40 Million in Series B Funding Led by Leaps by Bayer to Overcome Food Allergies and Sensitivities Top industry leaders and venture firms unite behind Ukko's efforts to eliminate the world's most prevalent food allergies and sensitivities, including peanuts and gluten News provided by Share this article Share this article PALO ALTO, Calif., TEL AVIV, Israel and LEVERKUSEN, Germany, Jan. 27, 2021 /PRNewswire/ -- Ukko, a biotech company with the mission to eliminate food allergies and sensitivities, today announced $40 million in new Series B funding. Ukko harnesses artificial inte...